MA45381A - Formulation de vaccin contre le vih - Google Patents

Formulation de vaccin contre le vih

Info

Publication number
MA45381A
MA45381A MA045381A MA45381A MA45381A MA 45381 A MA45381 A MA 45381A MA 045381 A MA045381 A MA 045381A MA 45381 A MA45381 A MA 45381A MA 45381 A MA45381 A MA 45381A
Authority
MA
Morocco
Prior art keywords
vaccine formulation
hiv vaccine
hiv
formulation
vaccine
Prior art date
Application number
MA045381A
Other languages
English (en)
Inventor
Mark Bruner
Thierry-Thien NGUYEN
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MA45381A publication Critical patent/MA45381A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/38—Antigens from snakes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
MA045381A 2016-06-16 2017-06-15 Formulation de vaccin contre le vih MA45381A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662350919P 2016-06-16 2016-06-16

Publications (1)

Publication Number Publication Date
MA45381A true MA45381A (fr) 2021-04-21

Family

ID=59093548

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045381A MA45381A (fr) 2016-06-16 2017-06-15 Formulation de vaccin contre le vih

Country Status (14)

Country Link
US (3) US10273268B2 (fr)
EP (1) EP3471765B1 (fr)
JP (1) JP6595132B2 (fr)
KR (1) KR102389489B1 (fr)
CN (1) CN109219448B (fr)
AU (2) AU2017286375B2 (fr)
BR (1) BR112018075785A2 (fr)
EA (1) EA201892735A1 (fr)
IL (1) IL263624B (fr)
MA (1) MA45381A (fr)
MX (1) MX392862B (fr)
PH (1) PH12018502403A1 (fr)
SG (1) SG11201810549TA (fr)
WO (1) WO2017216288A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108368157B (zh) 2015-12-15 2022-04-15 扬森疫苗与预防公司 人类免疫缺陷病毒抗原、载体、组合物、及其使用方法
MX392862B (es) 2016-06-16 2025-03-24 Janssen Vaccines & Prevention Bv Formulación de vacuna contra el vih.
CN110494159A (zh) 2016-09-02 2019-11-22 扬森疫苗与预防公司 在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法
PT3512543T (pt) 2016-09-15 2020-10-13 Janssen Vaccines & Prevention Bv Trímero que estabiliza mutações das proteínas do envelope do hiv
WO2018229711A1 (fr) 2017-06-15 2018-12-20 Janssen Vaccines & Prevention B.V. Vecteurs à poxvirus codant pour des antigènes du vih, et leurs procédés d'utilisation
CA3069052A1 (fr) 2017-07-19 2019-01-24 Janssen Vaccines & Prevention B.V. Mutations de proteine d'enveloppe du vih stabilisant la forme trimere
EP3856238A1 (fr) * 2018-09-25 2021-08-04 Janssen Vaccines & Prevention B.V. Méthode d'induction d'une réponse immunitaire contre le virus de l'immunodéficience humaine par administration co-localisée de composants vaccinaux
CN114585639A (zh) 2019-11-07 2022-06-03 扬森疫苗与预防公司 蛋白质纯化
US12226431B2 (en) 2021-09-11 2025-02-18 Porosome Therapeutics, Inc. Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses
CN113750243A (zh) * 2020-06-02 2021-12-07 湖北盛齐安生物科技股份有限公司 一种用于提高囊泡稳定性的保护剂
CN114903922B (zh) * 2021-02-09 2024-04-26 武汉博沃生物科技有限公司 包含腺病毒的医药配制品及其保存方法
CN119390828A (zh) * 2024-12-31 2025-02-07 天津龙晟生物科技有限公司 人类免疫缺陷病毒hiv抗体及其应用和其检测产品

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3197825A (en) 1961-09-07 1965-08-03 Leonard W Hammond Core-pulling mechanism for casting dies
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
CA1341245C (fr) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Virus recombinant de la vaccine derive du virus modifie ankara
US5298416A (en) 1989-01-18 1994-03-29 British Technology Group Ltd. Attenuated polioviruses
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
WO1998014476A1 (fr) * 1996-10-04 1998-04-09 Amgen Inc. Compositions pharmaceutiques contenant un ligand mpl
US5761893A (en) 1996-10-22 1998-06-09 Lofquist Welding, Inc. Crop saving attachment for the snouts of combines
DK1818408T3 (da) 1999-05-17 2011-10-17 Crucell Holland Bv Rekombinant adenovirus af serotypen Ad11
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
WO2001019958A2 (fr) 1999-09-17 2001-03-22 Dana-Farber Cancer Institute, Inc. Trimeres stabilises solubles de glycoproteines
WO2002042480A2 (fr) 2000-11-23 2002-05-30 Bavarian Nordic A/S Variant du virus de la vaccine modified vaccinia ankara
WO2003004657A1 (fr) 2001-07-05 2003-01-16 Chiron Corporation Polynucleotides codant pour des polypeptides antigeniques du vih de sous-type b et/ou de sous-type c, polypeptides et leurs utilisations
JP4500049B2 (ja) 2001-12-04 2010-07-14 バヴァリアン・ノルディック・アクティーゼルスカブ フラビウイルスｎｓ１サブユニットワクチン
DK1497440T3 (da) 2002-04-25 2008-12-01 Crucell Holland Bv Stabile adenovirale vektorer og fremgangsmåder til propagering deraf
PT1497438E (pt) 2002-04-25 2010-02-04 Crucell Holland Bv Meios e métodos para a produção de vectores de adenovírus
WO2004044155A2 (fr) 2002-11-07 2004-05-27 Beth Israel Deaconess Medical Center Mip-1$g(a) et gm-csf adjuvants de la reponse immune
US7901690B2 (en) 2002-12-03 2011-03-08 University Of Massachusetts Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
AU2003299994A1 (en) * 2002-12-27 2004-07-29 Chiron Corporation Immunogenic compositions containing phospholpid
EP2363143A3 (fr) 2003-03-28 2012-02-15 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services MVA exprimant des gènes enveloppe, gag et pol du vih
EP1667631A4 (fr) 2003-09-15 2010-04-14 Novartis Vaccines & Diagnostic Approches combinees pour produire des reponses immunitaires
WO2005052119A2 (fr) 2003-11-19 2005-06-09 Beth Israel Deaconess Medical Center Adjuvants de la reponse immunitaire
EP1766097A4 (fr) 2004-06-15 2008-03-19 Progenics Pharm Inc Anticorps de neutralisation du vih-1 elicites par un complexe trimerique de glycoproteines d'enveloppe du vih-1
EP1784416B1 (fr) 2004-07-16 2011-10-05 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Vaccins contre le sida comprenant des constructions d'acides nucleiques cmv/r
EP2319860A3 (fr) 2004-08-27 2011-06-15 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Virus MVA de recombinaison exprimant les gènes modifiés env, gag et pol du VIH variantes A/G, B, et C
KR101253363B1 (ko) 2004-10-13 2013-04-15 베쓰 이스라엘 디코니스 메디칼 센터 인크 개선된 아데노바이러스 벡터 및 그것의 용도
CA2656741A1 (fr) 2005-07-06 2007-01-11 University Of Maryland Biotechnology Institute Immunogene a base d'enveloppe de vih de type limite presentant simultanement des sites de liaison de recepteur et de co-recepteur
CA2620874A1 (fr) 2005-08-23 2007-03-01 The Regents Of The University Of California Vaccin polyvalent
WO2007104792A2 (fr) 2006-03-16 2007-09-20 Crucell Holland B.V. Adénovirus recombinés basés sur les sérotypes 26 et 48 et utilisation de ceux-ci
CA2655934A1 (fr) * 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Proteines env vih trimeriques solubles stabilisees et leurs utilisations
CA2667358A1 (fr) 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Polypeptides d'enveloppe gp140 modifies en provenance d'isolats du vih-1, compositions, complexes trimeriques et utilisations de ceux-ci
WO2008140579A2 (fr) 2006-11-17 2008-11-20 New York University Induction d'anticorps neutralisants largement réactifs par la concentration de la réponse immunitaire sur les épitopes v3 de l'enveloppe gp120 du vih-1
HUE031411T2 (en) 2007-03-02 2017-07-28 Glaxosmithkline Biologicals Sa New Methods and Preparations
SMT202000101T1 (it) * 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
HRP20181776T1 (hr) 2008-11-18 2019-02-08 Beth Israel Deaconess Medical Center, Inc. Antivirusna cjepiva sa poboljšanom staničnom imunogenosti
WO2010096561A1 (fr) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protéines gag du vih/vis de synthèse et leurs utilisations
US9241986B2 (en) 2010-01-04 2016-01-26 Kj Biosciences Llc DPS fusion proteins for use in vaccines and diagnostics
NZ600629A (en) 2010-01-28 2014-12-24 Bavarian Nordic As Vaccinia virus mutants containing the major genomic deletions of mva
EP4549461A3 (fr) 2010-08-31 2025-08-06 Theraclone Sciences, Inc. Anticorps neutralisant le virus de l'immunodéficience humaine (vih)
AU2011316164B2 (en) 2010-10-15 2016-01-14 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara (MVA) influenza vaccine
WO2012082918A1 (fr) 2010-12-14 2012-06-21 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vaccins contre filovirus d'adénovirus de sérotype 26 et sérotype 35
WO2013036791A2 (fr) 2011-09-09 2013-03-14 Beth Israel Deaconess Medical Center, Inc. Vecteurs adénoviraux modifiés et procédés de traitement dans lesquels ils interviennent
EP2568289A3 (fr) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunosélection du virus de la stomatite vésiculaire recombinant exprimant les protéines du VIH-1 par des anticorps largement neutralisants
EP2766037A4 (fr) 2011-10-12 2015-08-05 Scripps Research Inst Mini boucle v3 de gp120 du vih-1 et ses utilisations
JP6345123B2 (ja) * 2012-02-16 2018-06-20 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
AU2013228096B2 (en) * 2012-03-05 2017-07-13 Intravacc B.V. Methods and compositions for stabilizing dried biological materials
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
EP2896015A4 (fr) 2012-09-13 2016-04-20 Parkland Ct For Clinical Innovation Système et procédé d'interface utilisateur pour tableau de bord clinique
WO2014047261A1 (fr) 2012-09-19 2014-03-27 Beth Israel Deaconess Medical Center, Inc. Virus associés à l'immunodéficience et l'entéropathie et procédés d'utilisation de ceux-ci
WO2014078688A2 (fr) 2012-11-16 2014-05-22 Beth Israel Deaconess Medical Center, Inc. Adénovirus recombinants et leur utilisation
SG10201705880QA (en) 2013-01-07 2017-08-30 Beth Israel Deaconess Medical Ct Inc Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
US10248758B2 (en) 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
US10376583B2 (en) 2013-09-30 2019-08-13 Beth Israel Deaconess Medical Center, Inc. Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator
JP2017507672A (ja) 2014-02-28 2017-03-23 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 複製型組み換えアデノウイルスベクター、組成物およびこれらの使用方法
WO2016037154A1 (fr) 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Protéines de l'enveloppe du vih-1 recombinantes et leur utilisation
PT3197489T (pt) 2014-09-26 2021-04-30 Beth Israel Deaconess Medical Ct Inc Métodos e composições para induzir a imunidade protetora contra a infeção pelo vírus da imunodeficiência humana
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
DK3271729T3 (da) 2015-03-18 2020-12-14 Janssen Vaccines & Prevention Bv Analyser til rekombinante ekspressionssystemer
CN108368157B (zh) 2015-12-15 2022-04-15 扬森疫苗与预防公司 人类免疫缺陷病毒抗原、载体、组合物、及其使用方法
MX392862B (es) 2016-06-16 2025-03-24 Janssen Vaccines & Prevention Bv Formulación de vacuna contra el vih.
CN110494159A (zh) 2016-09-02 2019-11-22 扬森疫苗与预防公司 在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法
PT3512543T (pt) 2016-09-15 2020-10-13 Janssen Vaccines & Prevention Bv Trímero que estabiliza mutações das proteínas do envelope do hiv

Also Published As

Publication number Publication date
JP6595132B2 (ja) 2019-10-23
AU2017286375A1 (en) 2018-12-06
CN109219448B (zh) 2022-09-20
IL263624A (en) 2019-01-31
PH12018502403A1 (en) 2019-09-16
MX2018015361A (es) 2019-03-11
CN109219448A (zh) 2019-01-15
IL263624B (en) 2022-04-01
US20210179670A1 (en) 2021-06-17
MX392862B (es) 2025-03-24
US20170362280A1 (en) 2017-12-21
US20190202870A1 (en) 2019-07-04
KR102389489B1 (ko) 2022-04-22
EP3471765B1 (fr) 2024-04-24
US10273268B2 (en) 2019-04-30
KR20190020020A (ko) 2019-02-27
WO2017216288A1 (fr) 2017-12-21
JP2019523773A (ja) 2019-08-29
AU2017286375B2 (en) 2019-04-18
EP3471765A1 (fr) 2019-04-24
CA3027454A1 (fr) 2017-12-21
BR112018075785A2 (pt) 2019-04-02
AU2019205994A1 (en) 2019-08-01
US10934328B2 (en) 2021-03-02
SG11201810549TA (en) 2018-12-28
EA201892735A1 (ru) 2019-05-31
US11603389B2 (en) 2023-03-14

Similar Documents

Publication Publication Date Title
MA45381A (fr) Formulation de vaccin contre le vih
MA46766A (fr) Vaccin antigrippal
EP3668541A4 (fr) Formulations de vaccin pneumococcique conjugué
SI3585803T1 (sl) Formulacije konjugiranega pnevmokoknega cepiva
MA43762A (fr) Vaccin contre le rsv
SI4070787T1 (sl) Farmacevtske formulacije
EP3603619A4 (fr) Formulation d'adjuvant vaccinal
MA42303A (fr) Formulations pharmaceutiques
PT3426294T (pt) Formulação farmacêutica compreendendo anticorpo, ciclodextrina e metionina
DK3634377T3 (da) Farmaceutisk formulering
EP3560512A4 (fr) Composition de vaccin contre le zona
DK3129007T3 (da) Vaccinesammensætninger
IL266537A (en) pharmaceutical preparation
IL253570A0 (en) Pharmacy composition
IL253177B (en) Pharmacy preparation
IL262745A (en) Improved preparations containing drugs
EP3383371C0 (fr) Formulation pharmaceutique
DK3280447T3 (da) Farmaceutiske formuleringer
EP3337463A4 (fr) Formulations pharmaceutiques
ZA201807851B (en) Pharmaceutical formulation
EP3439693A4 (fr) Nouvelles formulations de vaccin antipneumococcique
GB201506755D0 (en) Novel pharmaceutical formulation
DK3601277T3 (da) Farmaceutisk formulering
EP3891170A4 (fr) Immunogènes de vaccin contre le vih
EP3540057A4 (fr) Vaccin antipaludique